...
首页> 外文期刊>Tumour biology : >The histone demethylase lysine-specific demethylase-1–mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion
【24h】

The histone demethylase lysine-specific demethylase-1–mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion

机译:组蛋白脱甲基酶赖氨酸特异性脱甲基酶-1介导的KLF2表观遗传沉默有助于胃癌细胞的增殖,迁移和侵袭

获取原文
           

摘要

Gastric cancer is one of the most common malignancies and leading causes of cancer-related death worldwide. An increasing number of evidence has revealed that gastric tumorigenesis is a multistage pathological state, and epigenetic alterations are considered to play critical roles in the etiology of gastric cancer. Lysine-specific demethylase-1, a histone demethylase, has been linked to malignancy in several human cancers and considered to epigenetically regulate many tumor suppressor genes during tumorigenesis and cancer progression. However, its role and underlying targets in gastric cancer are still unclear. In this study, we detected the lysine-specific demethylase-1 expression level in gastric cancer tissues and cell lines and investigated the function and mechanism of lysine-specific demethylase-1 in the gastric cancer. The in vitro analysis shows that knockdown of lysine-specific demethylase-1 significantly inhibits gastric cancer cell proliferation, migration, and invasion and induces cell cycle G1 phase arrest and cell apoptosis. In vivo assays determine that lysine-specific demethylase-1 downregulation represses gastric cancer cell tumorigenesis. Mechanistic investigation reveals that tumor suppressor KLF2 is a key downstream target of lysine-specific demethylase-1 in gastric cancer. These findings indicate that lysine-specific demethylase-1 is an important oncogene in gastric cancer, and lysine-specific demethylase-1-mediated epigenetic repression of KLF2 plays a critical role in gastric cancer development and progression, which supports lysine-specific demethylase-1 as a potential therapeutic target in this disease.
机译:胃癌是全世界最常见的恶性肿瘤之一,也是与癌症相关的死亡的主要原因。越来越多的证据表明,胃肿瘤的发生是多阶段的病理状态,并且表观遗传学改变被认为在胃癌的病因中起着至关重要的作用。赖氨酸特异性脱甲基酶-1(一种组蛋白脱甲基酶)已与几种人类癌症中的恶性肿瘤相关,并被认为在肿瘤发生和癌症发展过程中表观遗传调控许多抑癌基因。然而,其在胃癌中的作用和潜在靶标尚不清楚。在这项研究中,我们检测了赖氨酸特异性脱甲基酶-1在胃癌组织和细胞系中的表达水平,并研究了赖氨酸特异性脱甲基酶-1在胃癌中的功能和机制。体外分析表明,赖氨酸特异性脱甲基酶-1的敲低显着抑制胃癌细胞的增殖,迁移和侵袭,并诱导细胞周期G1期阻滞和细胞凋亡。体内测定确定赖氨酸特异性脱甲基酶-1下调抑制胃癌细胞的肿瘤发生。机理研究表明,肿瘤抑制因子KLF2是胃癌赖氨酸特异性脱甲基酶1的关键下游靶标。这些发现表明,赖氨酸特异性脱甲基酶-1是胃癌的重要癌基因,赖氨酸特异性脱甲基酶-1介导的KLF2表观遗传抑制在胃癌的发生和发展中起着至关重要的作用,这支持赖氨酸特异性脱甲基酶-1。作为该疾病的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号